Shopping Cart
- Remove All
Your shopping cart is currently empty
WNK-IN-B is an inhibitor of Wnk signalling. WNK-IN-B is a cell-permeable diaminoacridine derivative that targets the CCT domain of SPAK and OSR1 via reversible binding. WNK-IN-B selectively suppress hypotonic shock-induced WNK signaling pathway activation in mpkDCT and MOVAS (100 µM) cultures without affecting p38 MAPK phosphorylation.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,470 | 6-8 weeks | |
| 50 mg | $1,910 | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks |
| Description | WNK-IN-B is an inhibitor of Wnk signalling. WNK-IN-B is a cell-permeable diaminoacridine derivative that targets the CCT domain of SPAK and OSR1 via reversible binding. WNK-IN-B selectively suppress hypotonic shock-induced WNK signaling pathway activation in mpkDCT and MOVAS (100 µM) cultures without affecting p38 MAPK phosphorylation. |
| Targets&IC50 | WNK4:16 μM (IC50), WNK1:34.4 μM (IC50) |
| Synonyms | WNK-IN-B, WNK IN B, Compound B |
| Molecular Weight | 333.38 |
| Formula | C20H19N3O2 |
| Cas No. | 332922-63-1 |
| Relative Density. | 1.299 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.